What we know about Eli Lilly's orforglipron If all goes well for Lilly, orforglipron could be up for FDA approval for weight management by the end of 2025, and for type 2 diabetes treatment in 2026
See an example of a recent study protocol that explores combining related supplements here, and consult broader trial reports such as the trial linked above for context
When discussing weight loss medicines, it is helpful to ask your GP or specialist about: Currently licensed and NICE-approved options available to you on the NHS or privately Eligibility criteria for specific treatments and what monitoring would be required Realistic expectations regarding weight loss outcomes, timescales, and the importance of lifestyle changes alongside medication Potential side effects , including gastrointestinal symptoms commonly associated with GLP-1 receptor agonists, and how these are managed If you experience any suspected side effects from a weight management medicine, you can report these directly to the MHRA via the Yellow Card Scheme (available at yellowcard.mhra.gov.uk)
There are a few different reasons these medications are believed to support fertility health
doi:10.1097/AOG.0b013e318250aeeb Lazarus J, Brown RS, Daumerie C, Hubalewska-Dydejczyk A, Negro R, Vaidya B
HMGB1 regulates ferroptosis through Nrf2 pathway in mesangial cells in response to high glucose